1 / 18

AMCo – new beginnings 20 th November 2013

AMCo – new beginnings 20 th November 2013 . John Beighton Medical Rep/Regional Manager - Smith Kline and French UK 1981-1990 Various sales and marketing jobs – SmithKline Beecham UK 1990-1997 Commercial Director – APS Berk/ Teva UK 1997-2002 Managing Director Teva UK 2002-2009

artie
Download Presentation

AMCo – new beginnings 20 th November 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AMCo – new beginnings20thNovember 2013

  2. John Beighton Medical Rep/Regional Manager - Smith Kline and French UK 1981-1990 Various sales and marketing jobs – SmithKline Beecham UK 1990-1997 Commercial Director – APS Berk/Teva UK 1997-2002 Managing Director Teva UK 2002-2009 VP Global Business Optimisation – Teva Pharmaceutical Ind. 2009 – 2010 CEO AMCo 2010 to date Presenter

  3. Company Origins “G word” Mar-12 Rebranding Oct-12 Aug-12 £367m £465m Jan-13 Refinancing

  4. Established 1991, Headquarters in South London Acquired by Cinven (Private Equity) August 2012 for £465 million 1991 ------ ------ £106 million 2012 Sales ------ ------ 80% Revenues in the United Kingdom ------ ------ 38 Countries with commercial presence ------ ------ Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) Rx ------ ------ Mercury Pharma

  5. Established 2002, Headquarters East of London. Acquired by Cinven (Private Equity) August 2012 for £367 million 2002 ------ ------ £109 million 2012 Sales ------ ------ 34% Revenues in the United Kingdom ------ ------ 100+ Countries with commercial presence ------ ------ Rx Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) ------ ------ Amdipharm

  6. ------ ------ Combined group rebranded AMCo in March 2013 UK Office to be relocated to Central London 2013 £248 million ------ ------ 2013 Expected revenues (15% Growth) ------ ------ 60% Revenues in the United Kingdom ------ ------ 112 Countries with commercial presence ------ ------ Rx Established Brands and Generics Virtual Business Model (R&D, Manufacturing outsourced) ------ ------ Amdipharm Mercury (AMCo)

  7. Acquisition History Eltroxin levothyroxine £27m 13 Countries Liothyronine liothyronine £10m 10 Countries Diamox acetazolamide £5m 27 Countries Hytrin terazosin £5m 21 Countries Hygroton chlortalidone £5m 12 Countries Ludiomil maprotiline £3m 25 Countries Cafergot ergotamine £2m 26 Countries 1992 2001 2006 2008 1999 2004 2007 2013 Macrodantin, Furadantin, Macrobid, Furabid nitrofurantoin £18m 18 Countries Neomercazole carbimazole £12m 20 Countries Erythrocin erythromicin £16m 32 Countries Akineton biperiden £7m 21 Countries Transact flurbiprofen £8m 2 Countries Fucithalmic fusidic acid £26m >90 Countries figures quoted are 2013 forecast revenues

  8. Management Team Robert Sully General Counsel Bharat Karbal Medical & Regulatory Brian McEwan Managing Director Amdipharm Guy Clark Strategic Development John Cowell Human Resources Vikram Kamath Finance Director John Beighton CEO Peter van Tiggelen CFO Jane Hill UK Commercial Simon Tucker International Commercial Karl Belk Global Operations

  9. Company Performance Sales History by Company 2010 to 2013 est. Millions

  10. Top 10 Molecules (Percentage of 2012 revenue) Codeine + paracetamol 5% Levothyroxine 11% Erythromicin 8% Flurbiprofen 5% Nitrofurantoin 7% Biperiden 4% Liothyronine 4% Carbimazole 4% Prednisolone 4% Cyclizine 3%

  11. AMCo Strategy • Consolidate strong position in UK • Off-patent brands and niche products

  12. UK Commercial Team Jane Hill UK Commercial Director Jeremy Devaney Hospitals Jenna Pritchard National Accounts Neil Cook Promoted Products

  13. AMCo Strategy • Focus on 5 Business Action Plans • Operational Excellence • Culture and Integration • Compliance – Quality and Reputation • International Excellence • Strategic Growth

  14. Global Coverage >50% of sales in UK AMCo offices/direct presence Distributor network

  15. International Excellence AMCo offices/direct presence Distributor network Target markets – direct presence

  16. Strategic Growth Brands Therapeutic Focus Licensing Development Acquisition Primary & Secondary Care Primary & Secondary Care • Low Competition • Stable Revenues and Profit • Multiple Markets • Growth Opportunities • Ophthalmology • Endocrinology • Urology • Infectious Diseases • Pain & Anaesthesia Dedicated business development team focused on driving revenue and profit growth Geographic Expansion Generics Companies & Products Primary & Secondary Care • Company acquisitions • Build out in Target Markets • Portfolio Optimisation • Distributor consolidation • Low Competition • Barriers to Entry • Branded Generics • Sustainable Pricing

  17. Strategic Development Activity • Portfolio Optimisation – registering existing AMCo products into new markets where the product isn’t currently registered or sold, and using the existing manufacturers to make the product • Product Development – creating new products with a contract development partner, whereby AMCo retains full ownership rights to the product, and freedom to choose who to manufacture the product • In-Licensing– buying the rights to sell a third party’s product in a defined territory, and agreeing for the licensor to supply the product to AMCo for an agreed period of time (typically 5 years) • Product Acquisitions– buying the permanent rights to own an existing product, in a defined territory (sometimes global e.g. Fucithalmic). The seller may wish to continue making the product, but more often would require AMCo to find a new supplier within 2-3 years

More Related